Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNASDAQ:HYPRNASDAQ:SURGNASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.43-6.5%$1.49$0.17▼$1.99$50.80M0.514.03 million shs55,154 shsHYPRHyperfine$0.70-2.7%$0.70$0.53▼$1.90$56.19M0.95897,125 shs304,919 shsSURGSurgePays$2.69+0.4%$2.79$1.05▼$3.75$52.66M0.43634,072 shs50,817 shsXAIRBeyond Air$0.29+58.7%$0.20$0.16▼$1.49$15.51M0.231.45 million shs36.20 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-4.76%-13.33%+1,030.43%+30.65%HYPRHyperfine-0.87%-7.56%+15.19%-21.54%-18.32%SURGSurgePays+3.88%-3.25%-5.96%+114.40%-29.47%XAIRBeyond Air+0.96%-4.77%-1.32%-36.69%-85.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AHYPRHyperfine3.2471 of 5 stars3.33.00.00.03.02.51.3SURGSurgePays3.1471 of 5 stars3.55.00.00.02.21.70.6XAIRBeyond Air4.2446 of 5 stars3.54.00.03.52.20.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AHYPRHyperfine 2.67Moderate Buy$1.0651.36% UpsideSURGSurgePays 3.00Buy$9.00234.57% UpsideXAIRBeyond Air 3.00Buy$1.50426.32% UpsideCurrent Analyst Ratings BreakdownLatest XAIR, HYPR, SURG, and CTCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.75 ➝ $9.006/3/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.20 ➝ $1.005/14/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.684/22/2025SURGSurgePaysAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.50 ➝ $8.753/24/2025HYPRHyperfineLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.503/20/2025HYPRHyperfineB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$1.50 ➝ $1.203/18/2025HYPRHyperfineWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$1.10 ➝ $1.29(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,546.92N/AN/A$1.07 per share2.27HYPRHyperfine$12.89M4.23N/AN/A$0.67 per share1.05SURGSurgePays$60.88M0.90N/AN/A$0.76 per share3.54XAIRBeyond Air$3.02M8.14N/AN/A$0.75 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AHYPRHyperfine-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/6/2025 (Estimated)SURGSurgePays-$45.73M-$2.79N/AN/AN/A-136.37%-206.01%-153.67%8/12/2025 (Estimated)XAIRBeyond Air-$60.24M-$1.06N/AN/AN/A-1,730.00%-226.01%-109.75%6/17/2025 (Estimated)Latest XAIR, HYPR, SURG, and CTCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/17/2025Q4 2025XAIRBeyond Air-$0.14-$0.09+$0.05-$0.09$1.39 millionN/A5/13/2025Q1 2025HYPRHyperfine-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million5/13/2025Q1 2025SURGSurgePays-$0.40-$0.38+$0.02-$0.38$9.80 million$10.58 million3/25/2025Q4 2024SURGSurgePays-$0.27-$0.93-$0.66-$1.02$8.22 million$9.59 million3/17/2025Q4 2024HYPRHyperfine-$0.16-$0.14+$0.02-$0.14$2.30 million$2.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AHYPRHyperfineN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29HYPRHyperfineN/A6.445.73SURGSurgePays0.086.244.70XAIRBeyond AirN/A3.563.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%HYPRHyperfine15.03%SURGSurgePays6.94%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%HYPRHyperfine30.98%SURGSurgePays30.50%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableHYPRHyperfine19077.83 million53.72 millionOptionableSURGSurgePays4020.41 million14.19 millionOptionableXAIRBeyond Air7086.37 million69.61 millionOptionableXAIR, HYPR, SURG, and CTCX HeadlinesRecent News About These CompaniesBeyond Air Reports Strong Revenue Growth and Strategic AdvancesJune 18 at 12:26 AM | tipranks.comBeyond Air, Inc. (XAIR) Q4 2025 Earnings Call TranscriptJune 17 at 10:05 PM | seekingalpha.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17 at 7:00 PM | finance.yahoo.comBeyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue EstimatesJune 17 at 6:16 PM | zacks.comBeyond Air Stock Dips After Mixed Q4 Results: Here's What To KnowJune 17 at 4:32 PM | benzinga.comBeyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJune 17 at 4:15 PM | globenewswire.comBeyond Air Submits PMA Supplement Application for Next-Generation LungFit PH II Nitric Oxide GeneratorJune 16 at 8:27 AM | quiverquant.comBeyond Air Submits FDA PMA Supplement for Next Generation LungFit® PHJune 16 at 8:00 AM | globenewswire.comBeyond Air (XAIR) to Release Quarterly Earnings on TuesdayJune 10, 2025 | americanbankingnews.comBeyond Oil Issues Clarification Regarding Previous German-Language Media ActivitiesJune 3, 2025 | globenewswire.comBeyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and WebcastMay 20, 2025 | globenewswire.comBeyond Air granted U.S. patent for gaseous nitric oxide deliveryApril 25, 2025 | markets.businessinsider.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)April 25, 2025 | finance.yahoo.comBeyond Air Gets Patent for Lung Infection TreatmentApril 25, 2025 | marketwatch.comBeyond Air granted U.S. patent for treatment of NTM infections using gaseous Nitric OxideApril 25, 2025 | msn.comBeyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung InfectionsApril 24, 2025 | quiverquant.comBeyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 23, 2025 | finanznachrichten.deNeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to AutismApril 21, 2025 | globenewswire.comNeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory BoardApril 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsMercadoLibre Is Soaring—Should You Wait for a Better Entry?By Ryan Hasson | May 26, 2025View MercadoLibre Is Soaring—Should You Wait for a Better Entry?Applied Digital's Strategic AI Play Gains MomentumBy Jeffrey Neal Johnson | May 21, 2025View Applied Digital's Strategic AI Play Gains Momentum$30B AI Opportunity: Will It Power Meta’s Next Surge?By Leo Miller | May 21, 2025View $30B AI Opportunity: Will It Power Meta’s Next Surge?Silver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?XAIR, HYPR, SURG, and CTCX Company DescriptionsCarmell NASDAQ:CTCX$2.43 -0.17 (-6.54%) As of 06/16/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.Hyperfine NASDAQ:HYPR$0.70 -0.02 (-2.74%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.67%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.SurgePays NASDAQ:SURG$2.69 +0.01 (+0.37%) Closing price 04:00 PM EasternExtended Trading$2.70 +0.02 (+0.56%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.Beyond Air NASDAQ:XAIR$0.28 +0.11 (+58.69%) Closing price 04:00 PM EasternExtended Trading$0.23 -0.05 (-18.60%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
